Teva Acquires Worldwide Rights to BXCL501 From BioXcel Therapeutics

• Teva completed its acquisition of BioXcel Therapeutics assets today, including worldwide rights to investigational agitation treatment BXCL501.
• FDA review covers at-home treatment of acute agitation associated with schizophrenia or bipolar I or II disorder in adults.
• If approved, BXCL501 would be the first FDA-approved at-home treatment for this condition, expanding the buyer's late-stage neuroscience pipeline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teva Pharmaceutical Industries Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610270800OMX_____CNEWS_EN_GNW1001280054_en) on October 27, 2026, and is solely responsible for the information contained therein.